Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Potential Risk as Cellectis Hit with Patent Infringement Lawsuit Over TALEN Gene-Editing Technology
Allogene Therapeutics Inc. disclosed that Factor Bioscience Inc. has filed a complaint in the United States District Court for the District of Delaware against Cellectis S.A. and its affiliate, alleging infringement of three U.S. patents related to gene-editing techniques. The complaint claims that Cellectis's TALEN-based gene-editing technology, which Allogene licenses for use in developing its allogeneic CAR T cell product candidates, infringes Factor's patented mRNA TALEN technology. AstraZeneca and certain affiliates are also named as defendants in the lawsuit for direct infringement. While Allogene is not currently a party to the litigation, it relies on the disputed technology for key products and could face future claims as a commercial user. Cellectis has informed Allogene of its intent to vigorously defend against Factor's allegations. The situation poses intellectual property risks for Allogene, as outlined in its recent SEC filings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-044828), on October 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。